Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; gsk2857916) treatment in dreamm-2 study: 13-month follow-up

Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; gsk2857916) treatment in dreamm-2 study: 13-month follow-up

Introduction: Single-agent belamaf (BLENREP) demonstrated deep and durable responses in the DREAMM-2 (NCT03525678) primary analysis(1) and long-term follow-up.(2,3) Keratopathy (microcyst-like epithelial changes [MECs] observed on eye examination with/without symptoms) were managed through dose dela...

Full description

Bibliographic Details
Main Authors: A. Medaglia, A.D. Cohen, H.C. Lee, S. Trudel, A-O. Abdallah, N. Callander, E. Libby, L. Karlin, S. Lonial, L. Womersley, J. Baron, E. Lewis, K. Nungesser, I. Gupta, J. Opalinska
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Hematology Reports
Online Access:https://www.pagepress.org/journals/index.php/hr/article/view/8918

Internet

https://www.pagepress.org/journals/index.php/hr/article/view/8918

Similar Items